国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2013年
9期
779-781
,共3页
阿托伐他汀%川芎嗪%经皮冠状动脉介入术%心房颤动%高敏C-反应蛋白%基质金属蛋白酶-9
阿託伐他汀%川芎嗪%經皮冠狀動脈介入術%心房顫動%高敏C-反應蛋白%基質金屬蛋白酶-9
아탁벌타정%천궁진%경피관상동맥개입술%심방전동%고민C-반응단백%기질금속단백매-9
Atorvastatin%Ligustarazine%Percutaneous coronary intervention%Atrial fibrillation%High Sensitivity C Reactive Protein%Metal proteinase-9
目的 观察川芎嗪联合阿托伐他汀对经皮冠状动脉介入治疗术(percutaneous coronary intervention,PCI)后心房颤动(atrial fibrillation,AF)发生率的影响.方法 收集2010年3月至2012年5月广西医科大学第五附属医院心血管内科123例住院行急诊PCI治疗的急性冠脉综合征患者,按随机数字表法分为阿托伐他汀联用川芎嗪组(A组,25例),阿托伐他汀组(B组,30例),以及空白对照组(C组,68例).A组服用阿托伐他汀(40 mg/d)和川芎嗪片治疗；B组服用阿托伐他汀(40 mg/d);C组在术前半年内未使用任何调脂药物.观察三组患者术后2周内AF的发生率,72 h的高敏C-反应蛋白(hs-CRP)及基质金属蛋白酶-9 (MMP-9)的浓度,以及患者肝肾功能变化.结果 ①AF发生率比较:A组术后AF发生1例(4.0％),B组发生3例(10.0％),C组发生6例(8.8％),A组与B组、C组分别比较,差异均具有统计学意义(P值分别为0.023,0.028);②炎症因子水平变化比较:术后72h时A组hs-CRP、MMP-9的下降水平[分别为(16.13±15.22) mg/L、(345.77±300.25) μg-1]与B组[(23.77±19.25) mg-1、(390.58±296.75) μg-1]比较,差异有统计学意义(P=0.031).结论 阿托伐他汀联用川芎嗪能降低PCI术后患者AF的发生率,并显著降低炎症因子的水平,且具有较好的安全性.
目的 觀察川芎嗪聯閤阿託伐他汀對經皮冠狀動脈介入治療術(percutaneous coronary intervention,PCI)後心房顫動(atrial fibrillation,AF)髮生率的影響.方法 收集2010年3月至2012年5月廣西醫科大學第五附屬醫院心血管內科123例住院行急診PCI治療的急性冠脈綜閤徵患者,按隨機數字錶法分為阿託伐他汀聯用川芎嗪組(A組,25例),阿託伐他汀組(B組,30例),以及空白對照組(C組,68例).A組服用阿託伐他汀(40 mg/d)和川芎嗪片治療；B組服用阿託伐他汀(40 mg/d);C組在術前半年內未使用任何調脂藥物.觀察三組患者術後2週內AF的髮生率,72 h的高敏C-反應蛋白(hs-CRP)及基質金屬蛋白酶-9 (MMP-9)的濃度,以及患者肝腎功能變化.結果 ①AF髮生率比較:A組術後AF髮生1例(4.0％),B組髮生3例(10.0％),C組髮生6例(8.8％),A組與B組、C組分彆比較,差異均具有統計學意義(P值分彆為0.023,0.028);②炎癥因子水平變化比較:術後72h時A組hs-CRP、MMP-9的下降水平[分彆為(16.13±15.22) mg/L、(345.77±300.25) μg-1]與B組[(23.77±19.25) mg-1、(390.58±296.75) μg-1]比較,差異有統計學意義(P=0.031).結論 阿託伐他汀聯用川芎嗪能降低PCI術後患者AF的髮生率,併顯著降低炎癥因子的水平,且具有較好的安全性.
목적 관찰천궁진연합아탁벌타정대경피관상동맥개입치료술(percutaneous coronary intervention,PCI)후심방전동(atrial fibrillation,AF)발생솔적영향.방법 수집2010년3월지2012년5월엄서의과대학제오부속의원심혈관내과123례주원행급진PCI치료적급성관맥종합정환자,안수궤수자표법분위아탁벌타정련용천궁진조(A조,25례),아탁벌타정조(B조,30례),이급공백대조조(C조,68례).A조복용아탁벌타정(40 mg/d)화천궁진편치료；B조복용아탁벌타정(40 mg/d);C조재술전반년내미사용임하조지약물.관찰삼조환자술후2주내AF적발생솔,72 h적고민C-반응단백(hs-CRP)급기질금속단백매-9 (MMP-9)적농도,이급환자간신공능변화.결과 ①AF발생솔비교:A조술후AF발생1례(4.0％),B조발생3례(10.0％),C조발생6례(8.8％),A조여B조、C조분별비교,차이균구유통계학의의(P치분별위0.023,0.028);②염증인자수평변화비교:술후72h시A조hs-CRP、MMP-9적하강수평[분별위(16.13±15.22) mg/L、(345.77±300.25) μg-1]여B조[(23.77±19.25) mg-1、(390.58±296.75) μg-1]비교,차이유통계학의의(P=0.031).결론 아탁벌타정련용천궁진능강저PCI술후환자AF적발생솔,병현저강저염증인자적수평,차구유교호적안전성.
Objective To study the effect of atorvastatin combained with ligustarazine on incidence of postoperative Atrial fibrillation(AF) after percutaneous coronary intervention and discuss the changes of inflammatory factors.Methods Ninety ACS patients were divided into three groups at random:25 cases of atorvastatin combined with iigustarazine treatment group (Group A),30 cases of Atorvastatin treatment group (Group B) and 68 cases of a control group (Group C).All of the patients were treated by PCI.The incidence of AF was observed during 2 weeks after PCI.The densities of high sensitivity C-reactive protein (hs-CRP)and metal proteinase-9 (MMP-9)in blood were examined after PCI for 72 hours.The changes of hepatic and renal functions were observed.Results ①The incidence of postoperative AF in group A was lower compared with group B (P=0.023) and C (P=0.028) ; there were no significant differences between group B and C.The levels of serum hs-CRP and MMP-9 in group A and group B were significantly decreased after PCI for 72 hours and large dose was more significant (P=0.031).②Tnere were no significant differences of hepatic and renal function among the three groups.Conclusion Atorvastatin combained with ligustarazine treatment before PCI may decrease the incidence of postoperative AF.The densities of serum hs-CRP and MMP-9 were decreased after the treatment of atorvastatin and large dose was more significant.
